Laboratory Corp Of America Holdings: Boston Partners Makes Purchase

February 13, 2018 - By Kurt Siggers

 Laboratory Corp Of America Holdings: Boston Partners Makes Purchase

Investors sentiment decreased to 0.9 in 2017 Q3. Its down 0.16, from 1.06 in 2017Q2. It is negative, as 41 investors sold Laboratory Corporation of America Holdings shares while 239 reduced holdings. 70 funds opened positions while 181 raised stakes. 91.79 million shares or 1.82% less from 93.49 million shares in 2017Q2 were reported.

Wellington Management Gp Limited Liability Partnership stated it has 759,102 shares or 0.03% of all its holdings. Norinchukin Bank & Trust The reported 7,578 shares stake. Mutual Of America Ltd holds 11,831 shares or 0.03% of its portfolio. 15,642 were reported by Cibc. Mercer Capital Advisers invested 0.02% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH). Stanley holds 1.26% or 31,352 shares in its portfolio. Hartford Management, a Connecticut-based fund reported 21,817 shares. Thompson Siegel & Walmsley Lc invested in 523,204 shares or 0.95% of the stock. Moreover, Montag & Caldwell Ltd has 0.02% invested in Laboratory Corporation of America Holdings (NYSE:LH) for 3,724 shares. Walleye Trading Ltd invested in 2,961 shares or 0% of the stock. Sfe Counsel, a California-based fund reported 11,239 shares. Boston Prtn stated it has 0.86% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH). Gam Holdg Ag holds 0.07% or 11,252 shares in its portfolio. Jane Street Grp Inc Ltd Co has invested 0% in Laboratory Corporation of America Holdings (NYSE:LH). Hussman Strategic Advisors reported 0.02% stake.

Since August 25, 2017, it had 0 buys, and 4 sales for $12.26 million activity. Another trade for 1,263 shares valued at $213,813 was sold by Schechter Adam H. 31,500 Laboratory Corporation of America Holdings (NYSE:LH) shares with value of $4.89M were sold by EBERTS F SAMUEL III. Shares for $7.01M were sold by KING DAVID P on Wednesday, September 6.

The New Boston Partners Holding in Laboratory Corp Of America Holdings

Boston Partners reported SC 13G form with the SEC for Laboratory Corp Of America Holdings. Access it here: 000108514618000656. As reported by Boston Partners, the filler owns 5.23% or 5,324,442 shares of the Health Care–company.

Laboratory Corp Of America Holdings stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Boston Partners’s positive view for Laboratory Corp Of America Holdings. For a institutional investor managing $53.18 billion in assets and having 126+ experts this is interesting position.

Laboratory Corp Of America Holdings Institutional Sentiment

Filings show 575 investors own Laboratory Corp Of America Holdings. The ownership in Q3 2015 is extremely high, at Infinity of the outstanding shares. This is increased by 368767. 94340354 were owned by these investors. 60 funds opened new Laboratory Corp Of America Holdings stakes, 216 increased positions. There were 56 that closed positions and 201 reduced them.

14 investors had the stock in their top 10. Some are: National Investment Services Inc Wi, Healthcor Management L.P., Allen Investment Management Llc, Weitz Investment Management Inc., Empyrean Capital Partners Lp, Mcrae Capital Management Inc, Ariel Investments Llc, Chieftain Capital Management Inc., Global Thematic Partners Llc, Security National Bank Of Sioux City Iowa Ia..

Catawba Capital Management is an investor bullish on Laboratory Corp Of America Holdings, owning 24443 shares as of Q3 2015 for 0.73% of its portfolio. Barry Investment Advisors Llc owns 8056 shares or 0.28% of its portfolio. CA Ami Asset Management Corp have 1.84% of its portfolio for 222129 shares. Further, Auxier Asset Management reported stake worth 0.11% of its portfolio. The NJ Advisors Capital Management Llc owns 14374 shares. Laboratory Corp Of America Holdings is 0.17% of its portfolio.

Business Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.

SEC Form 13G.

Boston Partners website.

Analysts await Laboratory Corporation of America Holdings (NYSE:LH) to report earnings on February, 15. They expect $2.40 earnings per share, up 11.63 % or $0.25 from last year’s $2.15 per share. LH’s profit will be $244.32M for 17.66 P/E if the $2.40 EPS becomes a reality. After $2.46 actual earnings per share reported by Laboratory Corporation of America Holdings for the previous quarter, Wall Street now forecasts -2.44 % negative EPS growth.

The stock increased 0.62% or $1.04 during the last trading session, reaching $169.53. About 250,312 shares traded. Laboratory Corporation of America Holdings (NYSE:LH) has risen 10.51% since February 13, 2017 and is uptrending. It has underperformed by 6.19% the S&P500.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory firm worldwide. The company has market cap of $17.26 billion. It operates through two divisions, LabCorp Diagnostics and Covance Drug Development. It has a 13.88 P/E ratio. The firm offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, tests for sexually-transmitted diseases, HCV tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Laboratory Corporation of America Holdings (NYSE:LH) Ratings Coverage

Among 19 analysts covering Laboratory Corp (NYSE:LH), 11 have Buy rating, 0 Sell and 8 Hold. Therefore 58% are positive. Laboratory Corp has $205 highest and $117 lowest target. $173.47’s average target is 2.32% above currents $169.53 stock price. Laboratory Corp had 56 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 17 by Zacks. On Tuesday, December 8 the stock rating was downgraded by Goldman Sachs to “Neutral”. UBS maintained the stock with “Neutral” rating in Tuesday, April 26 report. On Thursday, October 26 the stock rating was maintained by Barclays Capital with “Overweight”. The firm has “Buy” rating given on Tuesday, February 6 by Piper Jaffray. Robert W. Baird maintained the stock with “Hold” rating in Friday, September 1 report. On Tuesday, October 17 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Sector Weight” rating given on Tuesday, June 27 by KeyBanc Capital Markets. The firm earned “Buy” rating on Wednesday, February 7 by Craig Hallum. On Tuesday, April 26 the stock rating was maintained by Jefferies with “Hold”.

More recent Laboratory Corporation of America Holdings (NYSE:LH) news were published by: Seekingalpha.com which released: “Laboratory of America Holdings (LH) Q4 2017 Results – Earnings Call Transcript” on February 07, 2018. Also Nasdaq.com published the news titled: “Agree To Buy Laboratory Corporation of America Holdings At $175, Earn 16.9 …” on January 22, 2018. Nasdaq.com‘s news article titled: “Laboratory Corporation Of America Holdings Earnings Climb In Q4” with publication date: February 06, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: